Skip to content

Access to orphan medicines is becoming increasingly influenced by global pricing policy. As Most Favoured Nation (MFN) pricing and International Reference Pricing (IRP) become more closely interconnected, pharmaceutical companies are rethinking how they approach European launches, pricing strategies and patient access.

This whitepaper shares key insights from a pre-conference workshop at the World Orphan Drug Congress (WODC) USA, featuring Andrew Cummins (Sciensus) and Dee Chaudhary (Clarivate). Combining expert perspectives, live audience polling and interactive scenario discussions, it explores how MFN and IRP are reshaping the future of orphan drug commercialisation.

Download to discover:

  • How MFN is reshaping global pricing and launch strategy for orphan medicines
  • Why European pricing decisions now have wider commercial implications
  • The latest industry insights from live polling with rare disease leaders
  • How organisations are adapting launch sequencing and early access strategies
  • Practical considerations for managing pricing risk while protecting patient access

Download your free copy to explore the data and explore how MFN and IRP are transforming the future of European access and global launch strategy.

Sciensus

About Sciensus

Sciensus is a European leader in integrated end-to-end commercial services, supporting patients, health systems, providers and Biopharma companies. We offer distribution services, clinical care, digital solutions and patient insights to accelerate access to medicines and maximise product launches from clinical to full commercialisation. With over 30 years’ experience navigating the complex European healthcare ecosystem, Sciensus helps bring the right medicine to the right patients – faster.

Learn more